UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 393

Sortiert nach

Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial

Journal of thrombosis and haemostasis, 2008-04, Vol.6 (4), p.622-631

2008

Volltextzugriff (PDF)

Pharmacokinetics and safety of fibrinogen concentrate

Journal of thrombosis and haemostasis, 2009-12, Vol.7 (12), p.2064-2069

2009

Volltextzugriff (PDF)

Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-03, Vol.22 (2), p.232-239

2016

Volltextzugriff (PDF)

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency

Journal of thrombosis and haemostasis, 2018-02, Vol.16 (2), p.253-261

2018

Volltextzugriff (PDF)

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-09, Vol.23 (5), p.697-704

2017

Volltextzugriff (PDF)

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.619-627

2018

Volltextzugriff (PDF)

Prophylaxis vs. on-demand treatment with Nuwiq® (Human-cl rhFVIII) in adults with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-05, Vol.22 (3), p.374-380

2016

Volltextzugriff (PDF)

Long‐term tolerability, immunogenicity and efficacy of Nuwiq® (human‐cl rhFVIII) in children with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.595-603

2018

Volltextzugriff (PDF)

Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-03, Vol.22 (2), p.225-231

2016

Volltextzugriff (PDF)

Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia

Journal of thrombosis and haemostasis, 2006-07, Vol.4 (7), p.1634-1637

2006

Volltextzugriff (PDF)

Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-03, Vol.24 (2), p.211-220

2018

Volltextzugriff (PDF)

The first recombinant FVIII produced in human cells - an update on its clinical development programme

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-01, Vol.20 (s1), p.1-9

2014

Volltextzugriff (PDF)

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-01, Vol.22 (1), p.87-95

2016

Volltextzugriff (PDF)

Efficacy and safety of Nuwiq® (human‐cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-01, Vol.24 (1), p.70-76

2018

Volltextzugriff (PDF)

PO10 Nuwiq Dosing and Outcomes in the Management of Women/Girls with Haemophilia A Needing FVIII Treatment for Surgery - An International, Open-Label, Non-Controlled Study (NuDIMENSION)

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7, p.101975, Article 101975

2023

Volltextzugriff (PDF)

PB0584 Using Heparin-Calibrated Assays to Assess Anti-Factor Xa Activity of Factor Xa Inhibitors (FXaI): A Literature Correlation Analysis

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7, p.100733, Article 100733

2023

Volltextzugriff (PDF)

Antithrombin III in patients with severe sepsis: a pharmacokinetic study

Intensive care medicine, 2000-06, Vol.26 (6), p.704-715

2000

Volltextzugriff (PDF)

Researching and Enacting Change in Postsecondary Education: Leveraging Instructors' Social Networks

1, 2018

Volltextzugriff (PDF)

PB0840 Efficacy of Prophylaxis with a Plasma-Derived von Willebrand Factor/ Factor VIII Concentrate in Patients with von Willebrand Disease: Subgroup Analysis by Age and VWD Type

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7, p.101564, Article 101564

2023

Volltextzugriff (PDF)

Antithrombin, heparin, and heparan sulfate

Critical care medicine, 2002-05, Vol.30 (5 Suppl), p.S325-S331

2002

Volltextzugriff (PDF)

Demographic and clinical correlates of acute and convalescent SARS-CoV-2 infection among patients of a U.S. emergency department

The American journal of emergency medicine, 2021-10, Vol.48, p.261-268

2021

Volltextzugriff (PDF)

Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]

Critical care (London, England), 2002-08, Vol.6 (4), p.349-356, Article 349

2002

Volltextzugriff (PDF)

Pharmacokinetics and Dose Linearity of von Willebrand Factor /Factor VIII Concentrate (Humate-P®) in Elective Surgery in von Willebrand Disease Patients

Blood, 2005-11, Vol.106 (11), p.1792-1792

2005

Volltextzugriff (PDF)

Treatment of VWD Patients Requiring Elective Surgery with a Pasteurized von Willebrand Factor/FVIII Concentrate (Haemate®P) - The Use of a PK Guided Approach

Blood, 2005-11, Vol.106 (11), p.1781-1781

2005

Volltextzugriff (PDF)

A 19F NMR study of lomefloxacin in human erythrocytes and its interaction with hemoglobin

Journal of pharmaceutical and biomedical analysis, 1995-09, Vol.13 (10), p.1225-1233

1995

Volltextzugriff (PDF)

1 – 25 von 393

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(308)
Mit Volltextzugriff
(324)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial

Pharmacokinetics and safety of fibrinogen concentrate

Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A

Prophylaxis vs. on-demand treatment with Nuwiq® (Human-cl rhFVIII) in adults with severe haemophilia A

Long‐term tolerability, immunogenicity and efficacy of Nuwiq® (human‐cl rhFVIII) in children with severe haemophilia A

Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety

Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia

Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

The first recombinant FVIII produced in human cells - an update on its clinical development programme

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

Efficacy and safety of Nuwiq® (human‐cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures

PO10 Nuwiq Dosing and Outcomes in the Management of Women/Girls with Haemophilia A Needing FVIII Treatment for Surgery - An International, Open-Label, Non-Controlled Study (NuDIMENSION)

PB0584 Using Heparin-Calibrated Assays to Assess Anti-Factor Xa Activity of Factor Xa Inhibitors (FXaI): A Literature Correlation Analysis

Antithrombin III in patients with severe sepsis: a pharmacokinetic study

Researching and Enacting Change in Postsecondary Education: Leveraging Instructors' Social Networks

PB0840 Efficacy of Prophylaxis with a Plasma-Derived von Willebrand Factor/ Factor VIII Concentrate in Patients with von Willebrand Disease: Subgroup Analysis by Age and VWD Type

Antithrombin, heparin, and heparan sulfate

Demographic and clinical correlates of acute and convalescent SARS-CoV-2 infection among patients of a U.S. emergency department

Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]

Pharmacokinetics and Dose Linearity of von Willebrand Factor /Factor VIII Concentrate (Humate-P®) in Elective Surgery in von Willebrand Disease Patients

Treatment of VWD Patients Requiring Elective Surgery with a Pasteurized von Willebrand Factor/FVIII Concentrate (Haemate®P) - The Use of a PK Guided Approach

A 19F NMR study of lomefloxacin in human erythrocytes and its interaction with hemoglobin

Suchergebnisse filtern